Three companies are vying to gain the first approved drug for Duchenne muscular dystrophy in a race that has seen one company's stock soar 309% over the past year and the other two companies file to go public in recent weeks.

But even as investors focus on the three lead molecules, DMD researchers are already beginning to look toward a cocktail that would include earlier stage compounds and potentially treat a broader swath of the patient population.